A new perspective on metformin therapy in type 1 diabetes.

ABSTRACT: Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.

SUBMITTER: Livingstone R 

PROVIDER: S-EPMC5552844 | biostudies-other | 2017 Sep

REPOSITORIES: biostudies-other